Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis

Objectives: Previous studies have examined renal safety of once daily intravenous tobramycin in individuals with cystic fibrosis. This has been mainly in combination with ceftazidime in an adolescent or adult population. In this report, we describe our institutional experience of once daily intravenous tobramycin in combination with a variety of second anti-pseudomonal antibiotics in children with cystic fibrosis. Methods: We present a retrospective review including children with cystic fibrosis, who were admitted for a pulmonary exacerbation from January 2009 to December 2011, and treated using intravenous tobramycin. A literature review of once daily intravenous aminoglycoside dosing in cystic fibrosis was performed to compare our results to existing literature. Results: A total of 35 subjects were divided into once daily dosing (n = 20) versus multiple daily dosing (n = 15) groups. Mean age was 11.3 years (± 5.7) for the once daily dosing group and 13.1 years (± 4.4) for the multiple daily dosing group (p = 0.34). All subjects had normal baseline serum creatinine at admission (once daily dosing 0.49 ± 0.14 mg/dL vs multiple daily dosing 0.62 ± 0.23 mg/dL, p = 0.07). All subjects received intravenous tobramycin, and most received piperacillin-tazobactam as their second anti-pseudomonal antibiotic (once daily dosing 45% and multiple daily dosing 40%). There was no significant change in serum creatinine in either group during antibiotic treatment (once daily dosing 0.08 ± 0.12 mg/dL vs. multiple daily dosing 0.06 ± 0.10 mg/dL, p = 0.43). All subjects had significant improvement in lung function following intravenous antibiotic therapy. Conclusion: We show that both once daily dosing and multiple daily dosing of intravenous tobramycin in combination with a variety of second anti-pseudomonal antibiotics were safe in terms of nephrotoxicity in children with cystic fibrosis. These findings are important given existing literature mainly examines once daily tobramycin in combination with ceftazidime, a cephalosporin, and the majority of our patients were on tobramycin with piperacillin-tazobactam, an extended spectrum penicillin plus beta-lactam. This contributes new information not previously examined in a pediatric cystic fibrosis population.

[1]  C. Stockmann,et al.  Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides , 2013, Pediatric pulmonology.

[2]  N. Høiby,et al.  Respiratory bacterial infections in cystic fibrosis , 2013, Current opinion in pulmonary medicine.

[3]  A. Smyth,et al.  Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity , 2010, Current opinion in pulmonary medicine.

[4]  Karen A Robinson,et al.  Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations , 2009 .

[5]  M. Ballmann,et al.  Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis , 2009, Infection.

[6]  J. Ahern,et al.  A survey of once‐daily dosage tobramycin therapy in patients with cystic fibrosis , 2009, Pediatric pulmonology.

[7]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[8]  D. C. Griffith,et al.  Aerosol antibiotics: considerations in pharmacological and clinical evaluation. , 2008, Current opinion in biotechnology.

[9]  John A Kellum,et al.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.

[10]  R. Berger.  Extended-interval aminoglycoside administration for children: a meta-analysis. , 2005, The Journal of urology.

[11]  S. Lewis,et al.  Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial , 2005, The Lancet.

[12]  J. Ioannidis,et al.  Extended-interval aminoglycoside administration for children: a meta-analysis. , 2004, Pediatrics.

[13]  S. Bogle,et al.  Once-daily tobramycin in the treatment of adult patients with cystic fibrosis , 2002, European Respiratory Journal.

[14]  P. Baghurst,et al.  Efficacy of once‐daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: A preliminary study * , 2001, Pediatric pulmonology.

[15]  D. Turck,et al.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis , 1998, Archives of disease in childhood.

[16]  M. Nahata,et al.  Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. , 1997, Chest.

[17]  S. Teach,et al.  Laboratory Predictors of Fluid Deficit in Acutely Dehydrated Children , 1997, Clinical pediatrics.

[18]  A. Smyth,et al.  Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2012, The Cochrane database of systematic reviews.